96 related articles for article (PubMed ID: 26265240)
21. Chronic intragastric infusion of ethanol-containing diets induces CYP3A9 while decreasing CYP3A2 in male rats.
Rowlands JC; Wang H; Hakkak R; Ronis MJ; Strobel HW; Badger TM
J Pharmacol Exp Ther; 2000 Nov; 295(2):747-52. PubMed ID: 11046114
[TBL] [Abstract][Full Text] [Related]
22. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
Choi JS; Burm JP
Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964
[TBL] [Abstract][Full Text] [Related]
23. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
[TBL] [Abstract][Full Text] [Related]
24. The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain.
Haduch A; Bromek E; Daniel WA
Eur J Pharmacol; 2011 Jan; 651(1-3):51-8. PubMed ID: 21115002
[TBL] [Abstract][Full Text] [Related]
25. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
26. Thiomers: Inhibition of cytochrome P450 activity.
Iqbal J; Sakloetsakun D; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2011 Aug; 78(3):361-5. PubMed ID: 21362475
[TBL] [Abstract][Full Text] [Related]
27. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
28. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
29. Short-chain fatty acids oppositely altered expressions and functions of intestinal cytochrome P4503A and P-glycoprotein and affected pharmacokinetics of verapamil following oral administration to rats.
Zhang J; Xie Q; Kong W; Wang Z; Wang S; Zhao K; Chen Y; Liu X; Liu L
J Pharm Pharmacol; 2020 Mar; 72(3):448-460. PubMed ID: 31863502
[TBL] [Abstract][Full Text] [Related]
30. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
31. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
32. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m).
Streit M; Göggelmann C; Dehnert C; Burhenne J; Riedel KD; Menold E; Mikus G; Bärtsch P; Haefeli WE
Eur J Clin Pharmacol; 2005 Mar; 61(1):39-46. PubMed ID: 15692829
[TBL] [Abstract][Full Text] [Related]
34. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
36. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi DH; Li C; Choi JS
Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):163-8. PubMed ID: 20166433
[TBL] [Abstract][Full Text] [Related]
37. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Kharasch ED; Hoffer C; Walker A; Sheffels P
Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry.
Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
J Pharm Biomed Anal; 2007 Dec; 45(5):762-8. PubMed ID: 17981422
[TBL] [Abstract][Full Text] [Related]
39. DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A.
Zhu Y; Hu J; He W; Gao X; Ren P; Chen H
Chem Biol Interact; 2016 Mar; 247():55-63. PubMed ID: 26827781
[TBL] [Abstract][Full Text] [Related]
40. Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats.
Tian X; Cheng ZY; He J; Jia LJ; Qiao HL
Chem Biol Interact; 2013 Apr; 203(2):522-9. PubMed ID: 23458730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
